[Federal Register Volume 61, Number 223 (Monday, November 18, 1996)]
[Notices]
[Page 58694]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-29390]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 96N-0308]


Countrymark Cooperative, Inc.; Withdrawal of Approval of NADA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval 
of a new animal drug application (NADA) held by Countrymark 
Cooperative, Inc. The NADA provides for the use of tylosin Type A 
medicated articles to make Type C medicated feeds. Countrymark 
Cooperative requested the withdrawal of approval of the NADA because 
they are no longer making Type A medicated articles for use in Type C 
medicated feeds. In a final rule published elsewhere in this issue of 
the Federal Register, FDA is amending the regulations by removing those 
entries which reflect approval of the NADA.

EFFECTIVE DATE: November 29, 1996.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for 
Veterinary Medicine (HFV-216), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-594-1722.

SUPPLEMENTARY INFORMATION: Countrymark Cooperative, Inc., 950 North 
Meridian St., Indianapolis, IN 46204-3909 (formerly the Indiana Farm 
Bureau Cooperative Association, Inc., 120 East Market St., 
Indianapolis, IN 46204), has voluntarily requested withdrawal of 
approval of NADA 125-226 that provides for use of tylosin Type A 
medicated articles to make tylosin Type C medicated swine feeds.
    Therefore, under authority delegated to the Commissioner of Food 
and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary 
Medicine (21 CFR 5.84), and in accordance with Sec. 514.115 Withdrawal 
of approval of applications (21 CFR 514.115), notice is given that 
approval of NADA 125-226, and all supplements and amendments thereto is 
hereby withdrawn, effective November 29, 1996.
     In a final rule published elsewhere in this issue of the Federal 
Register, FDA is amending 21 CFR 510.600 and 558.625 to reflect 
withdrawal of approval of this NADA.

    Dated: October 18, 1996.
 Stephen F. Sundlof,
 Director, Center for Veterinary Medicine.
[FR Doc. 96-29390 Filed 11-15-96; 8:45 am]
BILLING CODE 4160-01-F